These include, firstly, a preclinical study in a porcine vitiligo model that demonstrated the blockade of one of the DAMPs associated with vitiligo; secondly, a preclinical study in which IL-15 was administered to a mouse model of vitiligo; and, thirdly, a preclinical study targeting the chemokine receptor CXCR3 [53,69]. This evidence concerns the gene IL15 and vitiligo.